Eterna Therapeutics (ERNA)
NASDAQ:ERNA
Total Valuation
Eterna Therapeutics has a market cap or net worth of $5.80M. The enterprise value is $168.76K.
Market Cap$5.80M
Enterprise Value$168.76K
Share Statistics
Eterna Therapeutics has 29,154,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,154,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Eterna Therapeutics’s return on equity (ROE) is -5.87 and return on invested capital (ROIC) is -316.61%.
Return on Equity (ROE)-5.87
Return on Assets (ROA)-2.42
Return on Invested Capital (ROIC)-316.61%
Return on Capital Employed (ROCE)-3.42
Revenue Per Employee0.00
Profits Per Employee-2.35M
Employee Count6
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eterna Therapeutics is ―. Eterna Therapeutics’s PEG ratio is -0.01.
PE Ratio―
PS Ratio0.00
PB Ratio3.15
Price to Fair Value3.15
Price to FCF-1.07
Price to Operating Cash Flow-0.22
PEG Ratio-0.01
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 0.00 and earned -14.10M in profits. Earnings per share was -2.24.
Revenue0.00
Gross Profit-263.00K
Operating Income-9.32M
Pretax Income-14.13M
Net Income-14.10M
EBITDA-9.06M
Earnings Per Share (EPS)-2.24
Cash Flow
In the last 12 months, operating cash flow was -7.02M and capital expenditures -37.00K, giving a free cash flow of -7.05M billion.
Operating Cash Flow-7.02M
Free Cash Flow-7.05M
Free Cash Flow per Share-0.24
Dividends & Yields
Eterna Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.43
52-Week Price Change-92.82%
50-Day Moving Average0.52
200-Day Moving Average1.27
Relative Strength Index (RSI)23.49
Average Volume (3m)147.10K
Important Dates
Eterna Therapeutics upcoming earnings date is Apr 14, 2023, TBA (Confirmed).
Last Earnings DateNov 8, 2022
Next Earnings DateApr 14, 2023
Ex-Dividend Date―
Financial Position
Eterna Therapeutics as a current ratio of 1.01, with Debt / Equity ratio of 20.41%
Current Ratio1.01
Quick Ratio1.01
Debt to Market Cap0.03
Net Debt to EBITDA0.15
Interest Coverage Ratio-345.15
Taxes
In the past 12 months, Eterna Therapeutics has paid -45.00K in taxes.
Income Tax-45.00K
Effective Tax Rate<0.01
Enterprise Valuation
Eterna Therapeutics EV to EBITDA ratio is -0.68, with an EV/FCF ratio of -0.88.
EV to Sales0.00
EV to EBITDA-0.68
EV to Free Cash Flow-0.88
EV to Operating Cash Flow-0.88
Balance Sheet
Eterna Therapeutics has $1.88M in cash and marketable securities with $490.00K in debt, giving a net cash position of $1.39M billion.
Cash & Marketable Securities$1.88M
Total Debt$490.00K
Net Cash$1.39M
Net Cash Per Share$0.05
Tangible Book Value Per Share$0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eterna Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―